Abstract
The respiratory syncytial virus (RSV) fusion (F) glycoprotein is highly immunogenic in its prefusion (pre-F) conformation. However, the protein is unstable, and its conformation must be stabilized for it to function effectively as an immunogen in vaccines. We present a mutagenesis strategy to arrest the RSV F protein in its pre-F state by blocking localized changes in protein structure that accompany large-scale conformational rearrangements. We generated a series of mutants and screened them in vitro to assess their potential for forming a stable pre-F. In animals, the immunogenicity of a representative mutant F protein, with a conformation confirmed by cryo-electron microscopy, elicited levels of neutralizing antibodies and protection against RSV-induced lung damage that were comparable to those of DS-Cav1, a pre-F used in a licensed vaccine.
MeSH terms
-
Animals
-
Antibodies, Neutralizing / immunology
-
Antibodies, Viral / immunology
-
Cryoelectron Microscopy
-
Humans
-
Immunogenicity, Vaccine
-
Lung / virology
-
Mice
-
Mice, Inbred BALB C
-
Mutagenesis
-
Mutation
-
Protein Conformation
-
Protein Stability
-
Respiratory Syncytial Virus Infections* / immunology
-
Respiratory Syncytial Virus Infections* / prevention & control
-
Respiratory Syncytial Virus Vaccines* / chemistry
-
Respiratory Syncytial Virus Vaccines* / genetics
-
Respiratory Syncytial Virus Vaccines* / immunology
-
Respiratory Syncytial Virus, Human* / genetics
-
Respiratory Syncytial Virus, Human* / immunology
-
Viral Fusion Proteins* / chemistry
-
Viral Fusion Proteins* / genetics
-
Viral Fusion Proteins* / immunology
Substances
-
Antibodies, Neutralizing
-
Antibodies, Viral
-
F protein, human respiratory syncytial virus
-
Respiratory Syncytial Virus Vaccines
-
Viral Fusion Proteins